Anti-inflammatory reliever therapy for asthma

Brian Lipworth (Lead / Corresponding author), Rory Chan, Chris RuiWen Kuo

Research output: Contribution to journalArticle

Original languageEnglish
JournalAnnals of Allergy, Asthma & Immunology
Early online date11 Oct 2019
DOIs
Publication statusE-pub ahead of print - 11 Oct 2019

Cite this

@article{acdbbd003354484fbed2ceed861685db,
title = "Anti-inflammatory reliever therapy for asthma",
author = "Brian Lipworth and Rory Chan and {RuiWen Kuo}, Chris",
note = "Dr Lipworth reported receiving grants, personal fees, and nonfinancial support from Astra Zeneca (UK); grants, personal fees, and nonfinancial support from Chiesi (Italy); and other support from GSK (UK) during the conduct of the study and grants, personal fees, and nonfinancial support from Boehringer Ingelheim (Germany) and personal fees from Sanofi (France), Teva (Israel), Novartis (Switzerland), Cipla (India), Circassia (UK), Vectura (UK), Glenmark (UK), Dr Reddys (India), Lupin (USA), Genentech (USA), outside the submitted work. Dr Kuo reported receiving personal fees from Circassia (UK) and AstraZeneca (UK) outside the submitted work. No other disclosures were reported.",
year = "2019",
month = "10",
day = "11",
doi = "10.1016/j.anai.2019.10.002",
language = "English",
journal = "Annals of Allergy, Asthma & Immunology",
issn = "1081-1206",
publisher = "Elsevier",

}

TY - JOUR

T1 - Anti-inflammatory reliever therapy for asthma

AU - Lipworth, Brian

AU - Chan, Rory

AU - RuiWen Kuo, Chris

N1 - Dr Lipworth reported receiving grants, personal fees, and nonfinancial support from Astra Zeneca (UK); grants, personal fees, and nonfinancial support from Chiesi (Italy); and other support from GSK (UK) during the conduct of the study and grants, personal fees, and nonfinancial support from Boehringer Ingelheim (Germany) and personal fees from Sanofi (France), Teva (Israel), Novartis (Switzerland), Cipla (India), Circassia (UK), Vectura (UK), Glenmark (UK), Dr Reddys (India), Lupin (USA), Genentech (USA), outside the submitted work. Dr Kuo reported receiving personal fees from Circassia (UK) and AstraZeneca (UK) outside the submitted work. No other disclosures were reported.

PY - 2019/10/11

Y1 - 2019/10/11

U2 - 10.1016/j.anai.2019.10.002

DO - 10.1016/j.anai.2019.10.002

M3 - Article

C2 - 31610234

JO - Annals of Allergy, Asthma & Immunology

JF - Annals of Allergy, Asthma & Immunology

SN - 1081-1206

ER -